Compare Medtronic PLC (MDT) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Procter & Gamble Co — how do they compare? Medtronic PLC trades at $82.35 (market cap $106.61B), while Procter & Gamble Co trades at $147.45 (market cap $347.26B). The key difference: Procter & Gamble Co is far larger — about 3.3× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | PG | |
|---|---|---|
Market Cap | $106.61B | $347.26B |
Sector | Health | Consumer Staples |
52-Week High | $105.35 | $167.18 |
52-Week Low | $73.75 | $138.10 |
Enterprise Value | $125.36B | $372.74B |
Dividend Yield | 3.46% | 2.92% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Procter & Gamble (PG) trades at $147.47, down 1.66% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $161.71. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and a net margin of 18.95%. Recent quarterly earnings have consistently beaten expectations, and the company maintains a strong dividend history, with recent payouts of $1.09 per share.
PG offers stability with consistent earnings and dividend growth, but faces risks from premium valuations and modest revenue growth. The stock's upside is supported by operational efficiency gains and strong cash flow, though investor sentiment is mixed due to high P/E and P/S ratios relative to peers. Macroeconomic pressures and competitive dynamics remain key watchpoints for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
